Pediatric leukemia is a cancer of the blood-forming tissues, including the bone marrow. It develops when abnormal immature blood cells grow uncontrollably, interfere with the production of normal blood cells, and may enter the bloodstream or spread to other parts of the body.
Acute lymphoblastic leukemia is the most common childhood cancer and the most common type of pediatric leukemia. It develops from immature lymphoid cells and may be classified as B-cell or T-cell ALL. Acute myeloid leukemia develops from immature myeloid cells and is less common but generally requires more intensive treatment over a shorter period.
At Apollo Cancer Centres, pediatric leukemia is managed by a multidisciplinary team that may include pediatric hematologist-oncologists, hematopathologists, molecular specialists, stem-cell transplant and cellular-therapy teams, infectious-disease specialists, critical-care physicians, radiation oncologists, pharmacists, psychologists, dietitians, and rehabilitation professionals. Treatment is tailored according to leukemia type, genetic and molecular features, involvement outside the bone marrow, response to treatment, and measurable residual disease.
Risk Factors for Pediatric Leukemia
Pediatric Leukemia Signs and Symptoms
How Pediatric Leukemia Is Diagnosed
Chest X-ray
A chest X-ray may be performed when T-cell ALL is suspected or the child has cough, breathing difficulty, facial swelling, or prominent chest veins. It can show enlargement of the thymus or lymph nodes within the chest. A large mediastinal mass can compress the airway or major blood vessels. Anesthesia, sedation, and procedures must be planned carefully in this situation because lying flat or receiving certain medicines may worsen airway compression. Chest X-ray is not required to diagnose leukemia and may be omitted when there are no relevant symptoms or clinical findings.
Ultrasound
Ultrasound may be used to assess an enlarged liver or spleen, abdominal lymph nodes, kidneys, or other abdominal abnormalities. It may also evaluate testicular swelling or a suspected testicular leukemia deposit. Ultrasound does not use ionising radiation and usually does not require sedation. It is used selectively because physical examination and laboratory studies provide much of the information needed at diagnosis. The findings do not confirm leukemia but can help evaluate disease outside the bone marrow or identify another cause of symptoms.
CT Scan
CT may be used when detailed imaging of a chest or abdominal mass is required. It can show enlarged lymph nodes, organ involvement, infection, bleeding, or another complication. CT is not routinely required for staging every child with leukemia. Unnecessary radiation exposure is avoided, and imaging is selected according to symptoms and clinical findings. In children with a large chest mass, the need for CT and sedation is assessed carefully because airway or blood-vessel compression can make sedation unsafe.
MRI
MRI may be performed when neurological symptoms suggest involvement of the brain, spinal cord, nerves, or surrounding tissues. It may also help assess bone, joint, or soft-tissue abnormalities that remain unexplained. MRI provides detailed images without ionising radiation. Younger children may require sedation, which is planned according to their medical condition. Routine brain or spine MRI is not required for every child with leukemia. Cerebrospinal fluid assessment is the principal test for detecting leukemia cells within the central nervous system.
PET-CT
PET-CT is not routinely used to diagnose or stage pediatric leukemia. It may occasionally be considered when the diagnosis is uncertain, disease outside the bone marrow requires clarification, or another cancer is being evaluated. Because leukemia is a blood and bone-marrow cancer, its extent is determined primarily through blood, bone-marrow, cerebrospinal fluid, and molecular tests. Any PET-CT finding must be interpreted alongside pathology and laboratory results because infection and inflammation can also produce increased tracer uptake.
Bone-Marrow Aspiration
Bone-marrow aspiration is the principal procedure used to confirm acute leukemia. A needle is inserted, usually into the back of the pelvic bone, to collect liquid marrow. The sample is examined to determine the proportion and appearance of abnormal cells. Flow cytometry, chromosome studies, molecular testing, and baseline measurable residual disease testing may be performed on the same sample. The procedure is usually performed with sedation or anesthesia appropriate to the child's age and condition. Additional samples may be collected during treatment to assess response.
Bone-Marrow Biopsy
A bone-marrow biopsy removes a small cylinder of bone and marrow tissue. It provides information about marrow architecture and the pattern of abnormal-cell infiltration. Biopsy may be performed together with aspiration, particularly when the aspirate does not provide enough material or when fibrosis, marrow failure, or another bone-marrow disorder is suspected. The biopsy is examined by a hematopathologist and may undergo immunohistochemical and molecular testing.
Lumbar Puncture
A lumbar puncture collects cerebrospinal fluid from the lower back to determine whether leukemia cells are present around the brain and spinal cord. The fluid is examined through cytology and, in selected cases, flow cytometry. The procedure is planned after reviewing the child's platelet count, coagulation status, neurological condition, and risk of bleeding. Platelet transfusion may be required before the procedure. Intrathecal chemotherapy is often administered during the same procedure to prevent or treat central nervous system involvement. The timing of the first lumbar puncture depends on the child's clinical stability and treatment protocol.
Laboratory
Blood, bone-marrow, and cerebrospinal fluid samples may undergo:
Complete blood count: Measures red cells, white cells, platelets, and hemoglobin. Leukemia may cause low normal-cell counts, an increased or reduced white-cell count, and circulating blasts.
Peripheral blood smear: Allows specialists to examine the size, shape, and appearance of blood cells and identify abnormal immature cells.
Bone-marrow morphology: Determines the appearance and proportion of blasts and contributes to classification.
Flow cytometry: Identifies proteins on and within leukemia cells to determine whether the disease is B-cell ALL, T-cell ALL, AML, mixed-phenotype acute leukemia, or another subtype.
Cytogenetic testing: Evaluates the number and structure of chromosomes within leukemia cells.
FISH testing: Detects selected chromosome rearrangements, gains, or losses more rapidly than conventional chromosome analysis.
Molecular testing: Identifies gene fusions, mutations, and other alterations that may influence risk classification, targeted treatment, or clinical-trial eligibility.
Measurable residual disease testing: Uses sensitive flow-cytometric or molecular methods to detect small numbers of leukemia cells remaining during or after treatment.
Cerebrospinal fluid analysis: Determines whether leukemia cells are present within the central nervous system.
HLA typing: May be performed for the child and potential family donors when stem-cell transplantation could be required.
Germline testing: May be recommended when the child's age, family history, physical findings, blood counts, or tumour genetics suggest an inherited leukemia-predisposition syndrome.
Blood chemistry tests may include kidney and liver function, electrolytes, calcium, phosphate, uric acid, lactate dehydrogenase, and coagulation studies. These tests identify organ effects, tumour lysis risk, bleeding abnormalities, and treatment-related complications.
Blood cultures and infection tests may be performed when the child has fever or signs of infection. Treatment for a suspected serious infection should not be delayed while waiting for final culture results.
Pediatric leukemia is not staged from I to IV because it begins in the bone marrow and blood and is considered a body-wide disease from diagnosis. Instead, it is classified according to cell lineage, genetic and molecular features, disease outside the bone marrow, and response to treatment.
Leukemia Type
B-cell acute lymphoblastic leukemia: Develops from immature B lymphoid cells and is the most common childhood leukemia.
T-cell acute lymphoblastic leukemia: Develops from immature T lymphoid cells and may be associated with a mass in the chest.
Acute myeloid leukemia: Develops from immature myeloid blood-forming cells and includes several biological subtypes.
Mixed-phenotype acute leukemia: Shows both lymphoid and myeloid features and requires specialised classification and treatment.
Juvenile myelomonocytic leukemia: A rare myeloproliferative or myelodysplastic disease occurring mainly in young children.
Chronic myeloid leukemia: A rare childhood leukemia associated with the BCR::ABL1 fusion.
ALL Risk Classification
Childhood ALL may initially be classified using age and white-cell count:
Standard risk: Commonly includes children aged one to under ten years with a presenting white-cell count below 50,000 cells per microlitre.
High risk: Commonly includes children aged ten years or older or those with a presenting white-cell count of 50,000 cells per microlitre or higher.
A child initially classified as standard risk may require more intensive treatment if unfavourable biology or persistent measurable residual disease is identified.
AML Risk Classification
Childhood AML is classified using:
Cytogenetic and molecular alterations
Response to induction chemotherapy
Measurable residual disease
Presence of disease outside the bone marrow
Association with Down syndrome
Whether the disease developed after previous chemotherapy or radiation
Germline predisposition
Whether the leukemia is newly diagnosed, refractory, or recurrent
Children with favourable biological features and rapid clearance of leukemia may receive chemotherapy alone. Those with high-risk genetics or persistent disease may be considered for stem-cell transplantation.
How Pediatric Leukemia Is Treated
ALL Induction Therapy
Induction is the first phase of ALL treatment. Its aim is to achieve remission by reducing leukemia cells to a level that cannot be detected using routine microscopy. Treatment generally combines a corticosteroid, vincristine, asparaginase, and other chemotherapy according to risk group and protocol. Selected higher-risk patients may receive an anthracycline or additional medicines. Bone-marrow testing near the end of induction assesses remission and measurable residual disease. MRD results help determine the intensity of subsequent treatment.
ALL Consolidation and Intensification
Consolidation begins after remission and targets leukemia cells that remain in the body. It uses combinations of chemotherapy medicines delivered over several weeks or months. Additional intensification or delayed-intensification phases may be included to reduce relapse risk. The specific medicines, doses, and schedule depend on lineage, genetics, CNS status, and MRD response. Treatment may involve periods of hospital admission and outpatient care. Blood counts and organ function are monitored closely throughout each phase.
ALL Maintenance Therapy
Maintenance uses lower-intensity chemotherapy to suppress and eliminate remaining leukemia cells. It commonly includes daily oral and weekly medicines with additional protocol-defined treatments. Maintenance continues for a prolonged period, making the total duration of ALL therapy approximately two to three years in many protocols. The duration varies according to the regimen and risk group. Adherence to oral treatment is essential. The team monitors blood counts, liver function, medicine interactions, missed doses, and treatment-related effects.
AML Induction Therapy
AML treatment begins with intensive induction chemotherapy designed to achieve remission. Several medicines are combined over one or more courses. Treatment generally causes profound suppression of normal blood-cell production. Children commonly remain in hospital during periods of severe neutropenia and require transfusions, infection prevention, and rapid treatment of fever. Bone-marrow and MRD assessments determine response. The results help guide further chemotherapy and consideration of transplantation.
AML Consolidation Therapy
Consolidation aims to eliminate leukemia cells remaining after remission. It uses additional intensive chemotherapy courses and does not usually include the prolonged maintenance phase used for ALL. The medicines and number of cycles depend on molecular risk, MRD response, previous toxicity, and treatment protocol. Some children proceed to allogeneic stem-cell transplantation instead of completing chemotherapy alone. Recovery between courses is carefully monitored because infection, bleeding, and organ toxicity remain important risks.
Central Nervous System Therapy
All children with ALL receive treatment directed at the central nervous system because leukemia cells can survive in the cerebrospinal fluid even when none are detected at diagnosis. Intrathecal chemotherapy is administered through lumbar puncture at scheduled points during treatment. Systemic medicines that reach the central nervous system also contribute to disease control. Children with AML receive protocol-defined intrathecal treatment according to disease type and CNS findings. Cranial radiation is now reserved for uncommon, selected situations because effective chemotherapy can control CNS disease in most patients.
Targeted Therapy
Targeted medicines may be added when leukemia cells contain a relevant molecular alteration. Tyrosine kinase inhibitors are used for leukemias with BCR::ABL1 or selected related kinase alterations. Other targeted medicines may be considered for particular AML mutations or fusion-defined subtypes. Their use depends on age, treatment protocol, disease status, and available evidence. Molecular testing may be repeated if the leukemia returns because new treatment-relevant alterations can emerge over time.
Immunotherapy
Blinatumomab connects CD19-positive B-ALL cells with the patient's T cells. It may be used for persistent MRD, selected frontline treatment, or relapsed or refractory B-cell ALL. Inotuzumab ozogamicin targets CD22 and delivers a cell-killing medicine to B-ALL cells. It may be considered for selected children with relapsed or refractory disease. These treatments require monitoring for cytokine-release syndrome, neurological effects, liver injury, infection, and other complications. Their use is coordinated with subsequent chemotherapy, CAR-T therapy, or transplantation where appropriate.
Allogeneic Stem-Cell Transplantation
Allogeneic stem-cell transplantation replaces the child's blood-forming system with stem cells from a compatible donor. It may be considered for selected high-risk, persistent, refractory, or recurrent leukemias. Before transplantation, conditioning treatment is given to destroy remaining leukemia cells and suppress the immune system. Donor stem cells are then infused through a vein. Potential complications include infection, organ toxicity, infertility, graft-versus-host disease, and failure of the graft. The potential benefit is assessed against these risks using disease biology, MRD, donor availability, and previous treatment.
Donor Selection
A matched sibling may be the preferred donor when available, but matched unrelated, haploidentical family, and cord-blood donors may also be considered. HLA typing is performed to identify the most suitable donor. Selection also considers donor health, age, infection status, urgency, stem-cell source, and transplant-centre experience. Advances in supportive care and graft-versus-host disease prevention have expanded transplantation options for children without a fully matched sibling.
CAR-T Cell Therapy
CAR-T therapy uses the child's own T cells, which are collected and genetically modified to recognise a target on leukemia cells. CD19-directed CAR-T therapy may be considered for selected children and young people with relapsed or refractory B-cell ALL. The modified cells are returned after lymphodepleting chemotherapy. They can multiply within the body and attack CD19-positive leukemia cells. Treatment can cause cytokine-release syndrome, neurological effects, infection, and prolonged reduction of normal B cells. It must be delivered by a trained cellular-therapy team with intensive monitoring and access to appropriate emergency treatment.
Cranial Radiation Therapy
Cranial radiation is no longer routinely used for most children with ALL because modern intrathecal and systemic chemotherapy provides effective CNS control. It may be considered in uncommon, selected situations such as particular patterns of overt CNS disease, persistent CNS leukemia, or relapse. The decision depends on previous treatment, age, disease biology, and protocol. Potential long-term effects on learning, memory, growth, hormone function, blood vessels, and second-cancer risk are carefully considered.
Total-Body Irradiation
Total-body irradiation may be included in the conditioning regimen before allogeneic stem-cell transplantation for selected children, particularly those with high-risk ALL. It treats leukemia cells throughout the body and helps suppress the immune system before donor-cell infusion. Chemotherapy-only conditioning may be used in other situations. The choice depends on age, leukemia type, disease status, previous radiation, organ function, and transplant protocol. Long-term effects involving growth, hormones, fertility, lungs, eyes, and second-cancer risk require follow-up.
Local Radiation Therapy
Local radiation is used infrequently in pediatric leukemia. It may be considered for a persistent or recurrent mass, chloroma or myeloid sarcoma, testicular involvement, or another site not adequately controlled by systemic treatment. Radiation may also be used for urgent relief of compression affecting the brain, spinal cord, airway, or another critical structure. It does not replace systemic leukemia treatment. The dose and field are individualised to control disease while limiting exposure to growing tissues and nearby organs.
Central Venous Access
Surgery does not cure leukemia because the disease involves the blood and bone marrow throughout the body. However, a central venous catheter or implanted port is usually required for treatment. The device provides reliable access for chemotherapy, transfusions, antibiotics, fluids, blood sampling, and stem-cell therapy. Placement is planned according to the child's platelet count, infection status, anatomy, and expected duration of treatment. Families are taught how to care for the line and recognise infection, blockage, leakage, or thrombosis.
Management of Complications
Surgery may occasionally be required to manage a treatment complication, obtain tissue from an unusual mass, drain an infection, or address organ damage. These situations are uncommon and considered individually. Splenectomy and routine removal of enlarged lymph nodes have no standard role in treating acute childhood leukemia. Surgery should not delay systemic treatment unless an urgent complication requires intervention. The pediatric surgical and hematology teams coordinate timing to reduce bleeding, infection, and interruption of chemotherapy.
The outlook for pediatric leukemia varies according to disease type, genetics, age, initial white-cell count, organ involvement, and response to treatment. Many children with ALL can be treated successfully, while AML and rare leukemia types generally require more intensive therapy and have different outcomes.
MRD response is one of the most important indicators of relapse risk. Children whose leukemia clears rapidly generally have a more favourable outlook than those with persistent disease.
Long-term follow-up is required after treatment. Survivorship care may include monitoring of growth, puberty, fertility, learning, memory, heart and lung function, bone health, endocrine function, emotional well-being, and the risk of second cancers.
Why Choose ACC for Pediatric Leukemia Treatment